Meropenem Dosing for Hemodialysis Patients
The FDA label explicitly states there is inadequate information for meropenem dosing in hemodialysis patients, but based on pharmacokinetic research and clinical practice guidelines, administer 500 mg IV immediately after each hemodialysis session (three times weekly) for most infections, or 1 gram post-dialysis for severe infections or those caused by Pseudomonas aeruginosa. 1, 2
FDA-Approved Dosing Guidance
The FDA label for meropenem clearly states: "There is inadequate information regarding the use of meropenem for injection in patients on hemodialysis or peritoneal dialysis." 1
For patients with creatinine clearance <10 mL/min (not on dialysis), the FDA recommends one-half the standard dose every 24 hours. 1
Standard dosing in patients with normal renal function is 500 mg every 8 hours for skin/soft tissue infections and 1 gram every 8 hours for intra-abdominal infections. 1
Evidence-Based Dosing Recommendations for Hemodialysis
Post-Dialysis Administration Timing
Always administer meropenem immediately after completing the hemodialysis session, never before or during dialysis, as approximately 50% of the drug is removed during a standard 3–4 hour dialysis session. 2, 3, 4
Hemodialysis shortens meropenem's elimination half-life from approximately 7 hours (off dialysis) to 2.9 hours (during dialysis), making pre-dialysis dosing ineffective. 2
Post-dialysis dosing prevents premature drug removal and maintains therapeutic concentrations throughout the 48–72 hour interdialytic interval. 5
Specific Dose Recommendations
For most infections (skin/soft tissue, intra-abdominal): Give 500 mg IV immediately after each dialysis session, three times weekly (e.g., Monday/Wednesday/Friday). 5, 2
For severe infections or Pseudomonas aeruginosa coverage: Give 1 gram IV immediately after each dialysis session, three times weekly. 5, 1
Pediatric patients on hemodialysis should receive 20 mg/kg (maximum 500 mg) after each dialysis session, though a dose of 25 mg/kg or 40 mg/kg on alternate days may be needed to achieve optimal pharmacodynamic targets against P. aeruginosa. 4
Infusion Method
Administer as an IV infusion over 15–30 minutes for standard doses. 1
Doses of 1 gram may also be given as a bolus injection over 3–5 minutes if clinically appropriate. 1
Pharmacokinetic Rationale
Meropenem elimination half-life increases from approximately 1 hour in healthy individuals to 7.0–13.7 hours in anuric patients with end-stage renal disease. 2, 3
The drug is predominantly excreted unchanged in urine, making dosage adjustment essential in renal impairment. 3
Hemodialysis removes approximately 50% of circulating meropenem during a typical session, with more drug removed in the first 4 hours compared to the remainder of the session. 3, 6
High-flux dialyzers and varying blood flow rates (up to 150 mL/min) can significantly affect drug clearance. 6
Residual Renal Function Considerations
Patients with residual urine output of approximately 1 L/day do not require dose reduction beyond the standard post-dialysis regimen, as dialytic clearance remains the dominant elimination pathway. 5
The KDOQI guideline notes that while residual kidney function (estimated GFR 5–10 mL/min) may influence dialysis adequacy, it does not alter meropenem dosing requirements. 5
Critical Safety Considerations
Risk of Seizures
The recommended dose of 500 mg daily may still be too high in some patients, particularly those with smaller body mass index, as seizures have been reported even with "appropriate" dosing. 7
Central nervous system toxicity, including tonic-clonic seizures, can occur after multiple doses (e.g., after the 7th dose) and resolves completely upon drug discontinuation. 7
Consider dose reduction or alternative antibiotics in patients with additional risk factors for seizures or those of Asian descent with lower body weight. 7
Therapeutic Drug Monitoring
Therapeutic drug monitoring is strongly recommended in hemodialysis patients to ensure adequate drug exposure while avoiding toxicity. 5, 8
Target trough concentrations should be measured immediately before the next dialysis session to confirm adequate exposure during the interdialytic interval. 5
Patients with additional conditions such as diabetes with gastroparesis or those taking concurrent interacting medications may require careful pharmacologic assessment and serum drug concentration measurements. 9
Common Pitfalls to Avoid
Never administer meropenem before dialysis—this results in premature drug removal, subtherapeutic levels, and treatment failure. 5, 8
Do not reduce individual dose size—maintain standard per-dose amounts (500 mg or 1 gram) and extend the dosing interval to three times weekly instead. 8
Avoid daily dosing in hemodialysis patients—the three-times-weekly post-dialysis schedule aligns with the drug's clearance pattern during dialysis. 5, 8
Do not assume peritoneal dialysis dosing is the same—drug removal mechanisms differ, and specific data for peritoneal dialysis patients are lacking; begin with hemodialysis dosing and verify adequacy through serum concentration monitoring. 9, 1
Alternative Considerations for Continuous Renal Replacement Therapy
For patients on continuous venovenous hemofiltration (CVVH) or hemodialysis (CVVHD), meropenem clearance ranges from 2.74–3.4 L/h at standard blood flow rates, with 25–50% of the drug removed. 3, 10
Optimal dosing for CRRT typically requires 750 mg every 8 hours to achieve pharmacodynamic targets of 40% free drug time above 4× MIC. 10
Sustained low-efficiency dialysis (SLED) removes approximately 79% of plasma meropenem over an 8-hour session, and dosing 1 gram every 12 hours during SLED maintains adequate plasma concentrations. 6